Abstract: The present invention relates to a composition for the treatment of metabolic diseases, containing torsemide and cromolyn. According to the present invention, if torsemide and cromolyn are used in combination, compared to when cromolyn alone is used, weight is reduced, insulin resistance is reduced and liver fat accumulation is remarkably reduced in a NASH animal model, and thus the present invention can be effectively used in the prevention or treatment of metabolic diseases including diabetes, obesity, insulin resistance and metabolic liver diseases.
Abstract: A method, a device, and a computer program for predicting the interaction between a compound and a protein are provided. A method for predicting the interaction between a compound and a protein, according to some embodiments of the present disclosure, may include: acquiring compound data for training, protein data for training, and training data including interaction scores; constructing a deep-learning model by using the acquired training data; and predicting the interaction between the given compound and protein by using the constructed deep-learning model. The interaction between the given compound and protein in an in vivo environment can be accurately predicted by training the deep-learning model, while excluding, from an amino acid sequence of the protein for training, amino acid sequences associated with a protein domain having a negative influence on the interaction.
Abstract: The present invention relates to a pharmaceutical composition comprising calcium pantothenate, or calcium pantothenate and dimenhydrinate as active ingredients for prevention and treatment of myopathy. According to the present disclosure, calcium pantothenate upregulates the expression of MHC, myogenin 4-EBP, and p70S6K to promote myoblast differentiation and myogenesis, thereby prolonging the duration of life in amyotrophic lateral sclerosis patients and promoting the growth of MSC in Duchenne muscular dystrophy mice. Such effects are synergistically increased upon combined treatment with dimenhydrinate. Thus, they can be advantageously used for preventing or treating myopathy.
Abstract: The present disclosure relates to an effect of inhibiting cancer metastasis by treatment of chlorphenesin and hydroxychloroquine alone or in combination. Chlorphenesin or hydroxychloroquine has the effect of inhibiting the metastasis and invasion of cancer cells. In particular, since it was identified that a combination thereof has a synergistic action, it is possible to effectively prevent or treat cancer metastasis by administering chlorphenesin and hydroxychloroquine respectively or in combination thereof.
Type:
Application
Filed:
May 11, 2022
Publication date:
September 1, 2022
Applicant:
ONCOCROSS CO., LTD.
Inventors:
Yi-Rang Kim, Sang Yun Park, Ga Eul Yang, Seung Jun Lee
Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.
Abstract: The present invention relates to an anticancer and metastasis inhibiting effect by treatment with chlorphenesin, chloroquine, and chloropyrazine alone or in combination. Chlorphenesin, chloroquine, or chloropyrazine show the effect of killing cancer cells and inhibiting proliferation, and metastasis of cancer cells and particularly, a combination thereof is identified to have synergism. Cancer can be effectively prevented or treated by administering chlorphenesin, chloroquine, and chloropyrazine alone or in combination thereof.
Abstract: A pharmaceutical composition for preventing and treating liver diseases, includes cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.
Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.
Abstract: The present invention relates to an anticancer and metastasis inhibiting effect by treatment with chlorphenesin, chloroquine, and chloropyrazine alone or in combination. Chlorphenesin, chloroquine, or chloropyrazine show the effect of killing cancer cells and inhibiting proliferation, and metastasis of cancer cells and particularly, a combination thereof is identified to have synergism. Cancer can be effectively prevented or treated by administering chlorphenesin, chloroquine, and chloropyrazine alone or in combination thereof.
Abstract: A pharmaceutical composition for preventing and treating liver diseases, includes cromolyn or a pharmaceutically acceptable salt thereof as an active ingredient.